Drug Approval | October 19, 2021
MSN Labs launches drug for diabetes management
The company claims that its Empagliflozin tablets are the most affordable in India
The company claims that its Empagliflozin tablets are the most affordable in India
The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
It has planned an investment of over Rs 80 crore in the next five years
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
Subscribe To Our Newsletter & Stay Updated
